Genprex, Inc. GNPX 深 滬
等待開盤 10-21 09:30:00 美东时间
0.28
-0.083
-22.84%
華盛通- 最 高0.351
- 今 開0.3433
- 成交量 1723.79万股
- 最 低 0.267
- 昨 收 0.3629
- 總市值 1201.35万
- 52周最高 2.99
- 市盈率 靜 --
- 換手率 40.18%
- 52周最低 0.14
- 委 比 99.09%
- 總股本 4290.53万
- 歷史最高 778.00
- 量 比 0.08
- 振 幅 23.15%
- 歷史最低 0.14
- 每 手 1
- 風險率 3.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Genprex Announces Reverse Stock Split Amendment
An update from Genprex ( ($GNPX) ) is now available. On October 16, 2025, Genpr...
10-17 21:29
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT) rose sharply in pre-...
10-16 17:30
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
Q3 Virtual Investor Summit: On-Demand Presentations Now Available
NEW YORK, NY / ACCESS Newswire / September 30, 2025 / Investor Summit Group is ...
10-01 01:00
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
Gain announced the start of the Phase 1b extension study for GT-02287, allowing participants to continue treatment for an additional nine months. The Phase 1b study enrolled 21 subjects, with the final participants completing the initial 90-day dosing in December 2025. Early results will be presented at the International Congress of Parkinson’s Disease in October. Additional 90-day data, including biomarkers and functional assessments, are expect...
09-18 11:41
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ModivCare (NASDAQ:MODV) stock increased by 69.6% to $0.95 during Frida...
08-22 20:08
Genprex Secures Patent Allowances for Gene Therapy
Genprex ( ($GNPX) ) just unveiled an update. On August 18, 2025, Genprex announ...
08-18 21:47
Genprex Q2 EPS $(0.17) Beats $(0.42) Estimate
Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.42) by 59.52 percent. This is a 94.33 percent increase over losses of $(3.00) per share from the same
08-15 05:21
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas, Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("G...
08-04 20:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pluri (NASDAQ:PLUR) shares moved upwards by 24.0% to $5.99 during Tues...
07-02 05:05
